-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Maintains Buy on NewAmsterdam Pharma Co, Lowers Price Target to $46

Benzinga·11/05/2026 21:33:15
Listen to the news
Needham analyst Serge Belanger maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Buy and lowers the price target from $48 to $46.